Related Experiment Video
Updated: Jul 4, 2026
05:45
A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
Published on: January 16, 2026
Aerosolized STAT1 antisense oligodeoxynucleotides decrease the concentrations of inflammatory mediators in
Ming Zeng1, Bin Liao, Chen Zhu
1The Department of Respiratory Medicine, Affiliated Hospital of Luzhou Medical College, Luzhou, China.
Cellular & Molecular Immunology
|June 28, 2008
Summary
Aerosolized STAT1 antisense oligodeoxynucleotide (ASON) effectively reduced inflammation in rats with pulmonary fibrosis. This novel approach targets signal transducer and activator of transcription-1 (STAT1) in alveolar macrophages, showing promise for treating lung fibrosis.
Area of Science:
- Pulmonary Medicine
- Cell Biology
- Pharmacology
Background:
- Alveolar macrophages (AMs) are crucial in pulmonary fibrosis pathogenesis via cytokine release.
- Abnormal signal transducer and activator of transcription-1 (STAT1) activation in AMs is implicated in alveolitis and fibrosis.
Purpose of the Study:
- To investigate the therapeutic potential of STAT1 antisense oligodeoxynucleotide (ASON) delivered via aerosolization.
- To evaluate the effect of STAT1 ASON on inflammatory mediators in bleomycin-induced rat pulmonary fibrosis.
Main Methods:
- STAT1 ASON was aerosolized into rats with bleomycin-induced pulmonary fibrosis.
- Inhibition of STAT1 and ICAM-1 mRNA and protein expression in AMs was assessed.
- Levels of TGF-beta, PDGF, and TNF-alpha in bronchoalveolar lavage fluid (BALF) were measured.
Main Results:
- Aerosolized STAT1 ASON successfully entered lung tissues and AMs.
- STAT1 ASON inhibited STAT1 and ICAM-1 expression in AMs without causing liver or kidney toxicity.
- STAT1 ASON ameliorated alveolitis by reducing inflammatory mediator secretion.
Conclusions:
- Aerosolized STAT1 ASON demonstrates efficacy in reducing inflammation and ameliorating lung fibrosis in a rat model.
- This delivery method is well-tolerated and targets key inflammatory pathways.
- STAT1 ASON presents a promising new therapeutic strategy for pulmonary fibrosis treatment.
